T2 Biosystems, Inc. (TTOO)
NASDAQ: TTOO · Real-Time Price · USD
0.210
-0.010 (-4.55%)
At close: Jan 30, 2025, 4:00 PM
0.213
+0.003 (1.43%)
After-hours: Jan 30, 2025, 7:57 PM EST
T2 Biosystems Revenue
T2 Biosystems had revenue of $1.99M in the quarter ending September 30, 2024, with 34.85% growth. This brings the company's revenue in the last twelve months to $7.68M, down -30.19% year-over-year. In the year 2023, T2 Biosystems had annual revenue of $7.19M, down -67.75%.
Revenue (ttm)
$7.68M
Revenue Growth
-30.19%
P/S Ratio
0.30
Revenue / Employee
$67,938
Employees
113
Market Cap
4.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7.19M | -15.11M | -67.75% |
| Dec 31, 2022 | 22.31M | -5.75M | -20.50% |
| Dec 31, 2021 | 28.06M | 9.93M | 54.76% |
| Dec 31, 2020 | 18.13M | 9.80M | 117.52% |
| Dec 31, 2019 | 8.34M | -2.16M | -20.62% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.95B |
TTOO News
- 6 weeks ago - T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. - GlobeNewsWire
- 7 weeks ago - T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens - GlobeNewsWire
- 2 months ago - T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024 - GlobeNewsWire
- 4 months ago - T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript - Seeking Alpha
- 4 months ago - T2 Biosystems to Host Business Update Call on October 10, 2024 - GlobeNewsWire
- 4 months ago - T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens - GlobeNewsWire
- 4 months ago - T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union - GlobeNewsWire